Critical Outcome Technologies Inc. (COTI)

Critical Outcome Technologies Inc. (COTI)

June 23, 2014 09:00 ET

Critical Outcome Technologies Seeks to Redefine Personalized Cancer Care With Project ROSALIND

ROSALIND, a patent-pending cancer cell simulation, will be introduced at the upcoming BIO International Conference in San Diego

LONDON, ONTARIO--(Marketwired - June 23, 2014) - Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT)(OTCQB:COTQF), the bioinformatics and accelerated drug discovery company, announced today that Dr. Wayne Danter, President & CEO, will introduce "Project ROSALIND" in a podium presentation on June 25, 2014, at the annual BIO International Convention in San Diego California. The Company will use the hashtag #ROSALIND on Twitter for sharing more information with those not able to attend the presentation in person.

ROSALIND is a programmable computer simulation of cancer cell signaling, designed to realize the therapeutic potential of the important information derived from increasingly accessible cancer gene mutation profiles. The underlying principle behind ROSALIND is that cancers are diseases of cell signaling and any hope of sustained remission is dependent on therapies that restore normal cell signaling to regulate cell division and apoptosis.

"The goal of ROSALIND is to provide better personalized treatment options based on the genetic profile of the patient's cancer," said Dr. Wayne Danter. "While access to high-quality cancer gene mutation profiling continues to evolve, it has not been possible to use that information for truly personalized cancer therapy prior to ROSALIND. Personalized cancer therapy has been a big data problem. For example, the number of unique single, double, and triple drug combinations from just 150 cancer drugs would be in excess of 540,000. This is simply too many potential therapies for any physician or group of physicians to evaluate. ROSALIND addresses this big data problem."

"We are quite pleased with the results of our ongoing validation of this game-changing technology and are talking with a number of potential partners about commercial validation opportunities," added Dr. Danter.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit

Follow @CriticalOutcome on Twitter at

Notice to Readers

Information contained in this press release may contain certain statements, which constitute "forward-looking statements" within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statement, "… of this game-changing technology and are talking with a number of potential partners about commercial validation opportunities" is a forward-looking statement. Forward‐looking statements by their nature are not guarantees of future performance and are based upon management's current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward‐looking statements. Management of COTI considers the assumptions on which these forward‐looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information